You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for ELAHERE. Adverse event reporting information is at the bottom of this page.
1. ELAHERE SmPC
UK-ELAH-260244. Date of Preparation: August 2026
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for ELAHERE. Adverse event reporting information is at the bottom of this page.
1. ELAHERE SmPC
UK-ELAH-260244. Date of Preparation: August 2026
UK-ELAH-260246. Date of Preparation: August 2026
Resources
New content coming soon
We’re currently refreshing this page to bring you updated information and resources. Please check back soon to explore the new content.
New content coming soon
We’re currently refreshing this page to bring you updated information and resources. Please check back soon to explore the new content.
By clicking the link above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
UK-ELAH-260250. Date of preparation: November 2026.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
NICE Guidance (TA1169)1
Mirvetuximab soravtansine can be used, within its marketing authorisation, as an option to treat folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults after one to three lines of systemic treatment. Mirvetuximab soravtansine can only be used if the company provides it according to the commercial arrangement.1
NICE Guidance (TA1169)1
Mirvetuximab soravtansine can be used, within its marketing authorisation, as an option to treat folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults after one to three lines of systemic treatment. Mirvetuximab soravtansine can only be used if the company provides it according to the commercial arrangement.1
SMC accepted as a treatment option2
ELAHERE (MIRVETUXIMAB SORAVTANSINE) IS ACCEPTED FOR USE WITHIN NHS SCOTLAND.
Advice: following a full submission assessed under the end of life and orphan equivalent medicine process:
Indication under review: as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.2
SMC accepted as a treatment option2
ELAHERE (MIRVETUXIMAB SORAVTANSINE) IS ACCEPTED FOR USE WITHIN NHS SCOTLAND.
Advice: following a full submission assessed under the end of life and orphan equivalent medicine process:
Indication under review: as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.2
1. NICE 2026. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer [TA1169] Published 24 June 2026. Available at: https://www.nice.org.uk/guidance/ta1169 (Accessed November 2026).
1. NICE 2026. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer [TA1169] Published 24 June 2026. Available at: https://www.nice.org.uk/guidance/ta1169 (Accessed November 2026).
*By clicking the link you will leave the AbbVie Pro website to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium.
2. SMC 2026. Mirvetuximab soravtansine is accepted for use within NHSScotland as monotherapy for the treatment of adult patients with folate receptor- alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Published 12 October 2026 https://scottishmedicines.org.uk/medicines-advice/mirvetuximab-soravtansine-elahere-fullsmc2892/ (Accessed November 2026).
2. SMC 2026. Mirvetuximab soravtansine is accepted for use within NHSScotland as monotherapy for the treatment of adult patients with folate receptor- alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Published 12 October 2026 https://scottishmedicines.org.uk/medicines-advice/mirvetuximab-soravtansine-elahere-fullsmc2892/ (Accessed November 2026).
UK-ELAH-260245. Date of Preparation: November 2026